to Translate and Validate the TOPAS TORONTO PSORIATIC SCREENING QUESTIONNAIRE)Into Spanish
- Conditions
- Psoriatic Arthritis
- Registration Number
- NCT01891903
- Lead Sponsor
- Reumatologia Integral LTDA
- Brief Summary
TO TRANSALETE AND VALIDATE DE TORONTO PSORIATIC ARTHRITIS SECREENING QUESTIONAIRE INTO SPANISH
- Detailed Description
THIS IS PART OF THE COLOMBIAN REGISTRY OF PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- ADULT WITH PSORIASIS IN THE DERMATOLOGY CLINIC
Exclusion Criteria
- ADULT WITH OTHER AUTOIMMUNE DISEASE
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The Kuder Richardson Coefficient of reliability (K-R 20) 4 MONTHS
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular biomarkers are associated with psoriatic arthritis progression in psoriasis patients?
How does the Spanish version of TOPAS compare to standard screening tools for psoriatic arthritis in clinical practice?
What are the key cytokine pathways targeted in psoriatic arthritis therapies like IL-17 or IL-23 inhibitors?
Are there validated biomarkers for predicting response to biologic treatments in psoriatic arthritis?
What adverse event profiles are reported for current psoriatic arthritis treatment regimens including TNF-alpha inhibitors?
Trial Locations
- Locations (1)
Hospital Universitario Clinica San Rafael
🇨🇴Bogota, Cundinamarca, Colombia
Hospital Universitario Clinica San Rafael🇨🇴Bogota, Cundinamarca, ColombiaADRIANA BELTRAN, RHEUMATOLContact0573134327730adribeltr@yahoo.com